Lornoxicam Solid Lipid Nanoparticle-Enriched Transdermal Gel: Development and Characterization

To develop antiinflammation and analgesic effects, scientists introduced lornoxicam (LRX) nanoemulsion, nanostructure lipid carriers, and solid lipid nanoparticles. After six months of testing at different temperatures, SLN, NLC, and NE were determined to be stable. The most prominent mechanism that was identified in case I was the diffusional release of drugs from nanoparticles and nanoemulsion, which is consistent with Fickian drug diffusion. After NE, NLC, and SLN, a gel formulation achieved the greatest rate of drug penetration via rat skin. When contrasted with the gel, nanoformulations considerably enhanced the drug’s penetration into the skin of rats. Therefore, SLN, NLC, and NE of LRX could be recommended for the relief of skin disorders characterized by inflammation and pain.